CMA fines Advanz over ‘excessive and unfair’ pricing of thyroid drug
The £100m fine sends ‘a clear message’ to the pharma sector, said the CMA
Read More
Tag: Advanz Pharma
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
